Dr. Reddy's Laboratories’ wholly owned subsidiary -- Aurigene Discovery Technologies (Aurigene) has entered into an exclusive collaboration, option and license agreement with Exelixis, Inc.
The agreement gives Exelixis the opportunity to in-license as many as six programs from Aurigene, which has developed a focused approach to drug discovery that targets differentiated first-in-class and best-in-class opportunities with unique mechanisms of action. The deal is part of Exelixis' ongoing strategy to build an innovative pipeline behind the company's internally discovered, commercially available therapies, including its flagship product, CABOMETYX (cabozantinib).
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
